accessibilityaccreditedactiveactivityaimalarmalign-bottomalign-center-horizontalalign-center-verticalalign-leftalign-rightalign-topanchorangelannoyedapplearchivearrow-downarrow-leftarrow-rightarrow-uparticleat-signawardbalanceballoonbandaidbarcodebellbicyclebinocularsblindboatbook-closedbookbookmarkbookmarkedbooksbottlebriefcasebrushbugbullhornbuscabinetcakecalendarcameracarcashcertificatechalkchart-barschart-linechart-piechatcheckmarkchevron-downchevron-leftchevron-rightchevron-upcircle-arrow-downcircle-arrow-leftcircle-arrow-rightcircle-arrow-upcircle-backwardcircle-checkmarkcircle-chevron-downcircle-chevron-leftcircle-chevron-rightcircle-chevron-upcircle-crosscircle-ejectcircle-exclamationcircle-facebookcircle-firstcircle-forwardcircle-googlepluscircle-gustcircle-lastcircle-linkedincircle-minuscircle-nextcircle-pausecircle-play-thincircle-playcircle-pluscircle-previouscircle-questioncircle-stopcircle-twittercircleclipboard-checkclipboardclockcloud-databasecloud-downloadcloud-fogcloud-gearcloud-lightningcloud-lockcloud-raincloud-snowcloud-synccloud-uploadcloudcocktail-glasscodecombinecomment-fillcommentcommentscompassconfusedconnectconstruction-coneconstructioncontactscoolcopycredit-cardcropcrosscrowncubedatabasedeletedesigndesktopdiamonddicedinnerdisconnectdocumentdownloaddrawerdreamdropletdumbbellearthediteggellipsisenter-downenter-leftenter-rightenter-upenterenvelopeevilexcludeexit-downexit-leftexit-rightexit-upexitexpandeye-droppereyefacebookfactoryfeatherfile-audiofile-codefile-imagefile-videofile-zipfilefilm-playfindfirefirst-aidflagflip-horizontalflip-verticalfloppy-diskfolderfootprintframefunnelgamepadgasgeargiftglassglassesgoogleplusgraduationgrin-evilgringroupgungusthamburgerhammerhappy-grinhappyheadsetheart-fillhearthistoryhomeiconsinboxintersectipadiphonekeykeyboardkeyholeknifelablamplaptopleafleave-downleave-leftleave-rightleave-uplibrarylifebuoylighterlightning-boltlinklinkedinlistlocationlocklotusmadmagicmagnetmalletmanmapmedalmeet-downmeet-leftmeet-rightmeet-upmic-mutemicminusmoonmousemovemusic-notemusicmustachemutenavigationneutralnewsoptionsoutletpaint-rollerpaintbrushpairpaper-planepaperclippaperspastepatchpawpenpencilphonephotopicturepinpine-treeplaneplayplaylistplug-cordpluspodiumpowerpresentationprinterprofilepulsepuzzlequestionquote-closequote-openradiorank1rank2rank3receptionrecycleredorefreshregisterreply-allreplyroad-signrocketrulersadscissorsscreensearchshareshieldshipshirtshockedshrinkshufflesignalsitemapskullsmartphonesmilespeed-fastspeed-mediumspeed-slowspell-checksquaresubtractsunsyncsyringetabtablettagtagstargetteacupterminalthumbs-downthumbs-uptickettilestimertoilet-papertonguetoolstrailertraintransmissiontrashtreetrophytrucktvtwitterumbrellaundounlinkunlockuploaduserusersvolume-highvolume-lowvolume-mediumvolumewarningwheelchairwifiwinkwomanwonderingwrenchzoom-inzoom-out

Invest in Ligandal

Cell-specific delivery systems for gene editing tools

  • $1,398,802Amount raised
  • $10,000Minimum
  • $40,000,000Valuation cap

Purchased securities are not currently tradeable. Expect to hold your investment until the company lists on a national exchange or is acquired.

Ligandal is accepting investments for an Offering under Regulation D through SI Securities, LLC ("SI Securities"). SI Securities is an affiliate of SeedInvest Technology, LLC, a registered broker-dealer, and member FINRA/SIPC. SI Securities will receive cash compensation equal to 7.50% of the value of the securities sold and equity compensation equal to 5.00% of the number of securities sold. The contents of the Highlights, Term Sheet sections have been prepared by SI Securities, LLC (“SI Securities”) and shall be deemed broker-dealer communications subject to FINRA Rule 2210 (the “Excluded Sections”). With the exception of the Excluded Sections noted above, this profile contains offering materials prepared solely by Ligandal without the assistance of SI Securities, and not subject to FINRA Rule 2210 (the “Issuer Profile”). The Issuer Profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These statements reflect management’s current views with respect to future events based on information currently available and are subject to risks and uncertainties that could cause the company’s actual results to differ materially. Investors are cautioned not to place undue reliance on these forward-looking statements as they are meant for illustrative purposes and they do not represent guarantees of future results, levels of activity, performance, or achievements, all of which cannot be made. Moreover, no person nor any other person or entity assumes responsibility for the accuracy and completeness of forward-looking statements, and is under no duty to update any such statements to conform them to actual results.


Company Highlights

  • The Company has several international patents published (currently pending) and one patent granted, related to genomic editing and ligand-targeted modification
  • Initial commercial traction and statements of work with leading cell therapy and gene editing companies
  • Notable investors include Social Capital, Bioverge, and Chris Larsen of Ripple
  • Founder featured in Synthego’s The Bench Blog

Fundraise Highlights

  • Total Amount Raised: US $1,398,802
  • Total Round Size: US $3,800,000
  • Raise Description:  Series A
  • Minimum Investment:  US $10,000 per investor
  • Security Type:  SAFE Note
  • Valuation Cap:  US $40,000,000

Gene therapy delivery is 20 years behind our knowledge of what's wrong in different disease states. Ligandal wants to make genomics actionable, by allowing us to reprogram our adult physiology at a whim.


CRISPR, RNA and similar medicines are very powerful.

However, they require cell targeting technologies to actually enter the desired cell types, and reprogram those cells as we desire.

Without advancements in delivery technology, gene therapy will remain limited to single doses of viruses (very expensive, immunogenic issues) and small sets of applications where cells can be permeabilized with mechanical or electrical means.

Ligandal is creating an innovative and novel targeting technology for gene therapies that is non-viral, cell targeted for specific cell types, and repeat dosable. The peptide-based materials cost $5/mg to manufacture. This means that gene therapies can become practical, efficacious, and broadly available for the masses.

Media Mentions

The Team

Founders and Officers

Andre founded Ligandal to enable reprogramming of biological systems with bioinspired nanomaterials and gene therapy. 

His goal is ultimately to extend human lives and create curative genomic therapies. In 2014, he created a non-viral system for delivering guided nucleases such as CRISPR and TALEN in vivo. This work may be the first demonstration of a cell-specifically targeted gene editing technology. He is an inventor on several pending or issued patent families relating to cell-specifically-targeted nanomedicine and gene therapy technologies. 

Andre splits his attention between financing, business development, IP and designing biomimetic peptides for targeting cells with gene therapies. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

Andre Watson

CEO

Andre founded Ligandal to enable reprogramming of biological systems with bioinspired nanomaterials and gene therapy. 

His goal is ultimately to extend human lives and create curative genomic therapies. In 2014, he created a non-viral system for delivering guided nucleases such as CRISPR and TALEN in vivo. This work may be the first demonstration of a cell-specifically targeted gene editing technology. He is an inventor on several pending or issued patent families relating to cell-specifically-targeted nanomedicine and gene therapy technologies. 

Andre splits his attention between financing, business development, IP and designing biomimetic peptides for targeting cells with gene therapies. His vision for Ligandal is to enable a new era in personalized medicine and globally accessible gene therapy.

Key Team Members

Ryan Spencer

CSO

Lacarya Scott

COO

Shuailiang Lin

Director of Genome Engineering

Sara Peyrot

Director of Biology

Diana Douglas

Executive Assistant to the CEO

Frequently Asked Questions

Making an Investment in Ligandal
How does investing work?

When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Ligandal. Once Ligandal accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Ligandal in exchange for your securities. At that point, you will be a proud owner in Ligandal.


What is the difference between preferred equity and a convertible note?

Preferred equity is usually issued to outside investors and carries rights and conditions that are different from that of common stock. For example, preferred equity may include rights that prevent or minimize the effects of dilution or grants special privileges in situations when the company is sold.

A convertible note is a unique form of debt that converts into equity, usually in conjunction with a future financing round. The investor effectively loans money to a startup with the expectation that they will receive equity in the company in the future at a discounted price per share when the company raises its next round of financing.

To learn more about startup investment types check out “How to Choose a Startup Investment” in our academy.


What will I need to complete my investment?

To make an investment, you will need the following information readily available:

  1. Personal information such as your current address and phone number
  2. Employment and employer information
  3. Net worth and income information
  4. Social Security Number or passport
  5. ABA bank routing number and checking account number (typically found on a personal check or bank statement)

Because Ligandal is offering its securities under Rule 506(c) of Regulation D, your status as an Accredited Investor will also need to be verified and you will be asked to provide documentation supporting your income, net worth, revenue, or net assets or a letter from a qualified advisor such as a Registered Investment Advisor, Registered Broker Dealer, Lawyer, or CPA.


What if I change my mind about investing?

Until a closing occurs, you may cancel your investment at any time, for any reason. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your portfolio page by clicking your profile icon in the top right corner.


After My Investment
How can I sell my securities in the future?

Currently there is no market or liquidity for these securities. Right now Ligandal does not plan to list these securities on a national exchange or another secondary market. At some point Ligandal may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Ligandal either lists their securities on an exchange, is acquired, or goes bankrupt.


How do I keep track of this investment?

You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement.


Other General Questions
What is this page about?

This is Ligandal's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity.


What are the risks of this investment?

This investment is highly speculative and should not be made by anyone who cannot afford to risk the entire investment amount. In addition to these risks, you should carefully consider the specific information and risks disclosed in Ligandal’s profile.